Emcure hits the “sweet spot” on weightloss brand Poviztra, says executive

Emcure’s income from operations stood at ₹9,204 crore, up 16.6 per cent over final 12 months

Regardless of the slew of generically related variations of semaglutide not too long ago launched in India, Emcure Prescribed drugs expects its weightloss drug Poviztra (semaglutide injection) to be one in all its high manufacturers, Emcure executives mentioned, whilst the corporate crossed a milestone of $1 billion revenues for the 12 months ended March 31, 2026.

Emcure sells the innovator Novo Nordisk’s Wegovy below a second brandname, and earlier in April, it slashed costs on the product by over 50 p.c.

Full Would possibly

“We’ve proactively taken a really steep value reduce, and we actually consider that this value is now a candy spot,” Samit Mehta, Emcure Complete-Time director advised businessline, including that near 1000 medical representatives throughout divisions and specialities are focussed on selling the product. “We put the complete would possibly behind Poviztra. And the early indications, even after genericization, look constructive. Ultimately over the course of this 12 months, we anticipate this to be one of many high manufacturers for us,” he mentioned.

Satish Mehta, Chief Government Officer and Managing Director identified, that often there was an enormous differential between the innovator’s product and generics, after the patent expires.

“Right here, what has occurred due to the proactive method taken by Novo Nordisk, the distinction between generic and innovation isn’t very important. So clearly, we’ve a aggressive benefit due to the proper pricing technique or aggressive pricing technique backed up by science, scientific knowledge. And that’s paying dividends,” he added.

Semaglutide is the energetic ingredient in Danish healthcare main Novo Nordisk’s wieghtloss product Wegovy and diabetes product Ozempic. And with a primary patent on semaglutide expiring late-March in India, amongst different markets, quite a lot of generic drug makers launched their related variations, at 50 – 80 per cent of the innovator value. On this case, the innovator Novo Nordisk and companions Emcure and Abbott had additionally undertaken price-cuts, making the innovator product aggressive.

Monetary Efficiency

Emcure executives had been talking after the corporate introduced its monetary efficiency for the fourth quarter and FY26. The corporate’s income from operations stood at ₹9,204 crore, up 16.6 per cent over final 12 months; and its revenue after tax stood at ₹941 crore, up 33.1 per cent. Emcure’s This autumn income from operations stood at ₹2,470 crore, up 16.7 per cent over the identical interval final 12 months. Its PAT stood at ₹244 crore, up 23.6 per cent over This autumn, final 12 months.

Satish Mehta mentioned, “We strategically expanded by way of in-licensing, Zuventus minority buyoutand bolt-on acquisitions within the UK and Canada. Our R&D (analysis and growth) pipeline in complicated injectables and biosimilars stays a key driver of future worth.” The corporate may have a look at a neighborhood acquisition alternative in strategic therapeutic areas, he added.